Adjuvant Capital

Colorado-based biotech VitriVax announced Wednesday it has raised an undisclosed amount of Series A financing from Adjuvant Capital to develop and commercialize its Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology which reformulates vaccines for extended shelf life and can compress multidose regimens into a single shot.

The ALTA platform works by protecting antigens and adjuvants against thermal and chemical degradation at temperatures up to 70 degrees Celsius “for…

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

Belgium-based biomanufacturing platform company Univercells announced last week that it has completed a second round of Series C financing—adding $24 million to the $61 million it raised several months ago and bringing total funds raised this year to $146 million. This latest round of financing will support “distributed manufacturing and supply of biologics” and the development of GMP facilities to address “manufacturing bottlenecks for pandemics,” the press release said.

Funds from…

Denmark’s MinervaX announced Tuesday that it has raised $57 million to advance its protein-only Group B Streptococcus (GBS) vaccine candidate through Phase 2 and to prepare for Phase 3 trials.

According to the press release, the Series B round “included Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden”—along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment.

Rival Pfizer released positive Phase 1/2…

New York-based synthetic biology company Codagenix announced this week that it has added $20 million in Series B financing to its current $18 million in funding to support development of its live attenuated respiratory syncytial virus (RSV) vaccine, as well as a broadly-protective influenza shot and an oncolytic virus therapy for triple-negative breast cancer.

The financing will also enable the Stony Brook University spinoff to launch “two new vaccine development programs targeting…

Newly formed AN2 Therapeutics announced in a debut press release last week that an investor group, including Adjuvant Capital, has provided $12 million in initial financing to support its infectious-disease drug catalog.

The California-based company also revealed a licensing deal with North Carolina–based startup Brii Biosciences, which plans to develop, manufacture and commercialize AN2’s clinical-stage antibiotic for multidrug-resistant tuberculosis for the Chinese market.

Austria’s Themis Bioscience announced today that it has raised $44 million in Series D financing.

New investors were Farallon Capital Management and Hadean Ventures (which co-led the round) along with Merck and Adjuvant Capital. The Global Health Investment Fund and four other current investors also participated.

Themis said in a press release that it will spend the proceeds on Phase 3 trials of its chikungunya vaccine and on “further expansion into oncology indications using its…